These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37310968)

  • 1. How Media Stories in Low- and Middle-Income Countries Discussed the U.S. Food and Drug Administration's Modified Risk Tobacco Product Order for IQOS.
    Robichaud MO; Puryear T; Cohen JE; Kennedy RD
    Nicotine Tob Res; 2023 Aug; 25(10):1659-1666. PubMed ID: 37310968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. United States Food and Drug Administration's authorization of reduced exposure claims for IQOS
    Eckford R; Severini G; Sebrié EM; Muggli ME; Beem A; Rosen D; Crosbie E
    Rev Panam Salud Publica; 2022; 46():e155. PubMed ID: 36245905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA's reduced exposure marketing order for IQOS: why it is not a reliable global model.
    Lempert LK; Bialous S; Glantz S
    Tob Control; 2022 Aug; 31(e1):e83-e87. PubMed ID: 33811155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Social Media Discussions on the FDA's Modified Risk Tobacco Product Authorization of IQOS.
    Jun J; Zhang N; Zain A; Mohammadi E
    Subst Use Misuse; 2022; 57(3):472-480. PubMed ID: 34986075
    [No Abstract]   [Full Text] [Related]  

  • 5. IQOS: examination of Philip Morris International's claim of reduced exposure.
    St Helen G; Jacob Iii P; Nardone N; Benowitz NL
    Tob Control; 2018 Nov; 27(Suppl 1):s30-s36. PubMed ID: 30158205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IQOS Marketing Strategies and Expenditures in the United States From Market Entrance in 2019 to Withdrawal in 2021.
    Duan Z; Levine H; Romm KF; Bar-Zeev Y; Abroms LC; Griffith L; Wang Y; Khayat A; Cui Y; Berg CJ
    Nicotine Tob Res; 2023 Sep; 25(11):1798-1803. PubMed ID: 37338204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Modified Risk Tobacco Product Claims on Consumer Responses.
    Seidenberg AB; Boynton MH; Brewer NT; Lazard AJ; Sheeran P; Ribisl KM
    Nicotine Tob Res; 2024 Mar; 26(4):435-443. PubMed ID: 37791605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revolution or redux? Assessing IQOS through a precursor product.
    Elias J; Dutra LM; St Helen G; Ling PM
    Tob Control; 2018 Nov; 27(Suppl 1):s102-s110. PubMed ID: 30305324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smokers' Exposure to Perceived Modified Risk Claims for E-Cigarettes, Snus, and Smokeless Tobacco in the United States.
    Wackowski OA; O'Connor RJ; Pearson JL
    Nicotine Tob Res; 2021 Feb; 23(3):605-608. PubMed ID: 32812028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IQOS labelling will mislead consumers.
    McKelvey K; Popova L; Kim M; Lempert LK; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B
    Tob Control; 2018 Nov; 27(Suppl 1):s48-s54. PubMed ID: 30158208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Categorizing IQOS-Related Twitter Discussions.
    Barker JO; Vassey J; Chen-Sankey JC; Allem JP; Cruz TB; Unger JB
    Int J Environ Res Public Health; 2021 Apr; 18(9):. PubMed ID: 33946546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Informing iQOS Regulations in the United States: A Synthesis of What We Know.
    Berg CJ; Bar-Zeev Y; Levine H
    Sage Open; 2020; 10(1):. PubMed ID: 32719733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of industry data on pulmonary and immunosuppressive effects of IQOS.
    Moazed F; Chun L; Matthay MA; Calfee CS; Gotts J
    Tob Control; 2018 Nov; 27(Suppl 1):s20-s25. PubMed ID: 30158203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling the impact of a new tobacco product: review of Philip Morris International's Population Health Impact Model as applied to the IQOS heated tobacco product.
    Max WB; Sung HY; Lightwood J; Wang Y; Yao T
    Tob Control; 2018 Nov; 27(Suppl 1):s82-s86. PubMed ID: 30275170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel approach to assess the population health impact of introducing a Modified Risk Tobacco Product.
    Weitkunat R; Lee PN; Baker G; Sponsiello-Wang Z; González-Zuloeta Ladd AM; Lüdicke F
    Regul Toxicol Pharmacol; 2015 Jun; 72(1):87-93. PubMed ID: 25819932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PMI's own in vivo clinical data on biomarkers of potential harm in Americans show that IQOS is not detectably different from conventional cigarettes.
    Glantz SA
    Tob Control; 2018 Nov; 27(Suppl 1):s9-s12. PubMed ID: 30131374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IQOS print magazine advertising characteristics and reach before and after FDA authorisation as a modified risk tobacco product.
    Ganz O; Strasser AA; Giovenco DP; Audrain-McGovern J; Cappella JN; Safi Z; Tan ASL; Talbot EM; Delnevo CD
    Tob Control; 2023 Mar; ():. PubMed ID: 36958825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IQOS Marketing in the US: The Need to Study the Impact of FDA Modified Exposure Authorization, Marketing Distribution Channels, and Potential Targeting of Consumers.
    Berg CJ; Abroms LC; Levine H; Romm KF; Khayat A; Wysota CN; Duan Z; Bar-Zeev Y
    Int J Environ Res Public Health; 2021 Oct; 18(19):. PubMed ID: 34639851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heated tobacco products likely appeal to adolescents and young adults.
    McKelvey K; Popova L; Kim M; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B
    Tob Control; 2018 Nov; 27(Suppl 1):s41-s47. PubMed ID: 30352843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IQOS marketing strategies in the USA before and after US FDA modified risk tobacco product authorisation.
    Berg CJ; Romm KF; Bar-Zeev Y; Abroms LC; Klinkhammer K; Wysota CN; Khayat A; Broniatowski DA; Levine H
    Tob Control; 2023 Jul; 32(4):418-427. PubMed ID: 34667105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.